| Item | Detail | Source |
|---|---|---|
| Legal name | RH Bophelo Limited | FY2026 AFS |
| Former name | Newshelf 1388 Proprietary Limited | SENS, 5 Jul 2017 |
| Registration number | 2016/533398/06 | FY2026 AFS |
| Incorporated | 13 December 2016, Republic of South Africa | FY2026 AFS, note 1 |
| Founder | Quinton Zunga (founder, CEO) | TradingView profile; Business Day, Jul 2017 |
| Headquarters / registered office | Unit 12, 1st Floor, 1 Melrose Boulevard, Melrose Arch, Johannesburg, 2076 | FY2026 AFS; SENS 25 Nov 2025 |
| Primary listing | JSE Main Board, 12 July 2017; first listed as a SPAC and now an investment entity under Section 15 of the JSE Listings Requirements | SENS; Profile's Handbook 2025 |
| JSE sector classification | Financials – Closed End Investments | Profile's Handbook 2025 |
| Secondary listing | Rwanda Stock Exchange, by introduction, 1 June 2020 | FY2021 abridged results |
| Tickers | JSE: RHB (vendor alias RHBE; RHB.JO); RSE: RHB | SENS |
| ISIN | ZAE000244737 | SENS |
| CUSIP | Not applicable / not publicly disclosed (FIGI BBG00H416BS4 per TradingView) | TradingView |
| Fiscal year end | Last day of February | AFS |
| Shares in issue | 64,691,298 "A" ordinary shares, plus 1 unlisted "B" restrictive share held by the investment manager | FY2026 AFS, note 13 |
| Employees (holding company) | Not publicly disclosed. The holdco's employee costs were R9.31m in FY2026. | FY2026 AFS |
| Employees (Profile's Handbook) | 742. The scope is not stated and is likely group/portfolio-wide. | Profile's Handbook 2025 Issue 4 |
| Employee 3-year trend | Not publicly disclosed | — |
| Investment manager | RH Bophelo Management Company (Pty) Ltd (RHBM), external, which holds the "B" share | FY2026 AFS |
| External auditor | Forvis Mazars (formerly Mazars); engagement partner Stephan Adlam CA(SA) | FY2026 AFS |
| JSE sponsor | BSM Sponsors (Pty) Ltd. Previously Deloitte & Touche Sponsor Services; the change was made between Nov 2025 and May 2026. | FY2026 AFS; SENS 30 Jun 2026 |
| RSE sponsor | Faida Securities Rwanda Limited | FY2026 AFS |
| Company secretary | Statucor (Pty) Ltd. In 2021 it was Corporate Vision Consulting. | FY2026 AFS; FY2021 results |
| Transfer secretary | Computershare Investor Services (Pty) Ltd | SENS |
| B-BBEE status | Level 1 | SENS, 27 Jul 2026 |
| Net asset value (NAV), FY2026 | R1,096,831,961; NAV per share 1,695.5 cents | FY2026 AFS |
| Market capitalisation (current) | About R106.7m at 165c/share × 64.69m shares (analyst-derived). TradingView displays R112.56m (see note). | TradingView, Oct 2026 |
| Price / NAV | About 0.10x, a discount of roughly 90% to reported NAV (analyst-derived) | — |
| Website | www.rhbophelo.co.za | SENS |
RH Bophelo is a small, black-owned, Johannesburg-based investment holding company. It allocates permanent capital to South African healthcare and healthcare-adjacent financial services. It listed on the JSE in 2017 as a R500m special purpose acquisition company and later converted into a Section 15 investment entity. It now holds about R1.15bn of unlisted portfolio investments, all measured at fair value. Roughly 78% of that value sits in an "asset-heavy" cluster of independent, mostly peri-urban private hospitals and related property companies: Africa Healthcare, Rondebosch Medical Centre, Medicare, Vryburg, RH Bell and Fauchard. The remaining ~21% sits in an "asset-light" cluster of pharmaceutical distribution (MMed/1-Pharma), radiology (RazoHealth), dialysis (Renal Healthcare Africa), pathology (Ambit/Pelo) and benefits administration (Wesmart). Its stated purpose is affordable care for lower- and middle-income South Africans. The investment case hinges on the gap between a reported NAV of R16.96 per share and a thinly traded share price of about R1.65. That gap is shaped by external management, a concentrated register dominated by the Public Investment Corporation, and Level-3 valuations.
---
### Company's own description (FY2026 AFS, paraphrased)
The company describes itself as an investment entity listed on the JSE and RSE. It seeks returns for shareholders through equity, quasi-equity and equity-related investments in healthcare and financial services. It names the target areas as operational infrastructure, health insurance, private hospital infrastructure, pharmaceuticals, retail and distribution, and healthcare technology.
It executes this mandate through two wholly owned investment-entity subsidiaries:
- **RH Bophelo Operating Company (Pty) Ltd (RHBO)**, which holds healthcare investments.
- **RH Financial Services (Pty) Ltd (RHFS)**, which holds healthcare-related financial services investments.
Portfolio management is outsourced under a shareholder-approved management agreement to RH Bophelo Management Company (Pty) Ltd (RHBM). RHBM is not controlled by the company (FY2026 AFS, notes 1 and 4.1).
In FY2026 the company described its strategy as a deliberate move from an "asset-heavy owner and operator" of healthcare facilities to an "asset-light owner and manager of healthcare assets". The aim is to participate in the broader healthcare value chain through partnerships, scalable operating models and new ventures in pharmacy distribution, pathology, radiology and dialysis (FY2026 AFS, Directors' Report, note 9).
### Independent characterisation
Economically, RH Bophelo is a listed, externally managed, permanent-capital private equity vehicle. It invests in a concentrated set of unlisted South African healthcare businesses. Several features follow from its accounting status:
1. **Revenue model.** Under IFRS 10 the company and its two sub-holding companies qualify as investment entities. The company therefore does not consolidate its hospitals or distribution businesses. Its "revenue" is made up of:
- dividends received from RHBO;
- interest on shareholder loans (mainly the Notamed/RH Bell property loan) and on cash;
- fair-value gains or losses on the portfolio, which are unrealised and Level-3.
No look-through product, service or subscription revenue mix is published in the AFS. The FY2025 Integrated Annual Report summary on AfricanFinancials (an AI-generated summary, unaudited) states that asset-light businesses contributed 32% of "Group revenues" and were growing at more than 15% a year. The underlying Rand revenue is not disclosed in the sources retrieved.
2. **Value-chain position.** Through its investees the company sits across several parts of the care chain:
- acute and day-hospital care: St Helena (Welkom), Fochville, Carletonville, Vryburg, Rondebosch, Medicare, RH Bell, Fauchard, and Platinum via Dorama;
- hospital property ownership: Magnacorp, Notamed, St Helena property;
- pharmaceutical wholesale/distribution: MMed, now trading as 1-Pharma;
- diagnostics: RazoHealth radiology and Ambit/Pelo pathology;
- renal dialysis: Renal Healthcare Africa;
- nursing education: AHC Nursing College;
- emergency medical services: Gerijo EMS;
- medical-scheme/benefits administration: Wesmart.
In December 2021 the IFC described the company as owning eight hospitals and managing fourteen more for third parties through a hospital consulting, commissioning and management subsidiary. Whether that management business is still active is not disclosed in the FY2026 AFS.
3. **Customer types and end-markets.** The ultimate payers are medical schemes, insured individuals, self-paying lower- and middle-income patients and, to a degree, the state. At listing in 2017, management said it would serve people who cannot afford private care as currently structured, focusing on small independent hospitals in peri-urban areas (Business Day, July 2017). MMed sells to external pharmacies and to RH-owned pharmacies (FY2024 AFS, note 6.1).
4. **Mix of income (analyst-derived from AFS):**
Source: FY2024, FY2025 and FY2026 AFS, statements of profit or loss.
**Analytical note on the FY2026 dividend.** Dividend income rose to R83.69m in FY2026, but only R15.84m was received in cash (FY2026 cash flow statement). Dividends receivable increased by R11.73m, from R4.80m to R16.53m. The remaining ~R56.1m matches the R56.13m of "capital paid – non cash" on the Norsad loan almost exactly (FY2026 AFS, note 15). Our inference, which the company does not state explicitly, is that most of the FY2026 dividend was settled non-cash: the Norsad holding-company debt was discharged and refinanced at investee level (Africa Healthcare). The headline jump in dividend income is therefore largely a transfer of leverage from the holding company down to the portfolio, not an increase in cash yield.